[CANCERRESEARCH62,1573–1577,March1,2002]MeetingReportInternationalConsensusStatementonMalignantPeripheralNerveSheathTumorsinNeurofibromatosis11RosalieE.Ferner2andDavidH.Gutmann3DivisionofClinicalNeurosciences,DepartmentofNeuroimmunology,Guy’sKing’sandSt.Thomas’SchoolofMedicine,London,SE11ULUnitedKingdomAbstractNeurofibromatosis1(NF1)isanautosomaldominanttumorpredispo-sitionsyndromeinwhichaffectedindividualshaveagreatlyincreasedriskofdevelopingmalignantperipheralnervesheathtumors(MPNSTs).Thesecancersaredifficulttodetectandhaveapoorprognosis.Becausepatientsmaypresenttospecialistsfromwidelydifferingdisciplines,theassociationwithNF1isoftennotappreciated,andthereisnocohesivepatternofcare.Amultidisciplinarygroupof33cliniciansandscientistswithspecialistknowledgeinMPNSTandNF1reviewedthecurrentpublishedandunpublisheddatainthisfield,anddistilledtheircollectiveexperiencetoproduceaconsensussummaryonMPNSTinNF1.Theknownclinical,pathological,andgeneticinformationonMPNSTinNF1wascollated,andadatabasewasestablishedtorecordinformationinauniformmanner.SubgroupswithahigherriskofdevelopingMPNSTwereidentifiedwithintheNF1population.Theconsortiumformulatedproposalsandguidelinesforclinicalandpathologicaldiagnosis,surgicalmanagement,andmedicaltreatmentofMPNSTinindividualswithNF1.Amultidisciplinaryteamapproachtothemanagementofthiscomplexdisorderisadvocated.Progresscanbemadebyadoptingtheguidelinesproposedbythisconsortiumandbywidespreaddisseminationofstan-dardizedinformation.CollaborativeresearchshouldbepromotedwiththeaimofharnessingadvancesinmoleculargeneticstodeveloptargetedtherapiesforMPNSTinpeoplewithNF1.IntroductionNF14isanautosomaldominantneurocutaneousdisorder,withanestimatedbirthincidenceof1in2500(1).TheNF1geneonchro-mosome17q11.2wasidentifiedbypositionalcloning,anditsproteinproduct,neurofibromin,functionsasatumorsuppressor(2–4).Oneofthefunctionsofneurofibroministoreducecellproliferationbyacceleratingtheinactivationoftheproto-oncogenep21-ras,whichhasapivotalroleinmitogenicintracellularsignalingpathways(4).ThecardinalanddefiningfeaturesofNF1arecafe´aulaitmacules,neurofibromas,skinfoldfreckling,irisLischnodules,andcharacter-isticosseousdysplasia(5).Thecomplicationsofthedisorderarelegionandmayinvolveanyofthebodysystems(6).IndividualsaffectedwithNF1harboranincreasedriskofdevelop-ingbothbenignandmalignanttumors,supportingtheclassificationofNF1asatumorpredispositionsyndrome.ThemostcommontumorinindividualswithNF1istheneurofibroma,aheterogeneousbenignperipheralnervesheathtumor(7,8).Neurofibromasmayappearasdiscrete,dermalneurofibromas,focalcutaneousors.c.growths,dumbbell-shapedintraforaminalspinaltumors,ornodularordiffuseplexiformneurofibromas.Plexiformneurofibromasarecomposedofthesamecelltypesasdermalneurofibromasbuthaveanexpandedextracellularmatrixandoftenhavearichvascularsupply.Theydevelopalonganerveandmayinvolvemultiplebranches,nerveroots,andplexi.Impingementonsurroundingstructuresmaycausefunctionalcompromise,andsofttissueandbonehypertrophymayoccur(9).Plexiformneurofibromaswereclinicallyvisiblein30%of125NF1patientsinaSouthWalespopulationstudy(10).Fortyfourpercentofplexiformneurofibromas(32of72patients)werediagnosedbefore5yearsofageinoneclinic-basedstudy(11)suggestingthatmanyplexiformneurofibromasarecongenitallesions.Multipleplexiformneurofibromasoccurin9–21%ofcases(10–12).AlthoughMPNSTcandevelopinindividualsinthegeneralpopulation,individualswithNF1haveasignificantlyincreasedrisk.Thesetumorsarisefrequentlyinpreexistingplexiformneurofibromas,whichareveryuncommoninpeoplewhodonothaveNF1.MPNSTsareoftendifficulttodetect,metastasizetothelung,liver,brain,softtissue,bone,regionallymphnodes,skin,andretroperitoneum,andhaveapoorprognosis(13).BecausepatientswithMPNSTsmaypresenttospecialistsfromwidelydifferingdisciplines,theassociationwithNF1isoftennotappreciated,andthereisnoconsistentorwidelyacceptedpatternofcare.Aims.Inthisuniquemeeting,theaimwastoestablishaninterna-tional,multidisciplinaryconsortiumofexpertsonMPNSTandNF1.Thepurposewastocollatetheknownclinicalandgeneticinformationaboutthesetumorsandtosetupastandardizeddatabasetorecordinformationinauniformmanner.Inaddition,thegoalwastoformu-lateguidelinesforclinicalandpathologicaldiagnosis,surgicalman-agement,andmedicaltreatment.Moreover,strategieswereproposedfordevelopingtargetedtherapiesforNF1-associatedMPNSTs,takingintoaccounttherecentadvancesinmolecularbiology.MaterialsandMethodsAninternational,multidisciplinarygroupofcliniciansandscientistswithaspecialistinterestinsofttissuesarcomas(MPNST)andNF1wasinvited.Invitationsweresenttocliniciansworkinginspecialistsofttissuesarcomacentersorlargeneurofibromatosisclinicsandtoindividualswithresearchpublicationsinthesefields.Thecurrentknowledgeinthisfieldwasreviewedbasedonpersonalexpertiseandthemedicalliterature.Subsequently,thespecialistspooledtheircollectiveexperiencetoproduceaconsensusgroupsummaryonMPNSTinNF1.ResultsClinicalConsensusGroup.ItisgenerallyacceptedthatMPNSTsoccurinabout2–5%ofNF1patientscomparedwithanincidenceof0.001%inthegeneralpopulation(13).However,theremaybedif-ferencesincross-sectionalversuslongitudinaldeterminationsofriskReceived10/9/01;accepted1/04/02.Thecostsofpublicationofthisarticleweredefrayedinpartbythepaymentofpagecharges.Thisarticlemustthereforebeherebymarkedadvertisementinaccordancewith18U.S.C.Section1734solelytoindicatethisfact.1SupportedbyWellcomeTrust,TheBritishNeurofibromatosisAssociation,andCellPathways,Inc.2Towhomrequestsforreprintsshouldbeaddressed,atDivisionofClinicalNeuro-sciences,DepartmentofNeuroimmunology,SecondFloorHodgkinBuilding,Guy’sKing’sandSt.Thomas’SchoolofMedicine,LondonBridge,LondonSE11UL,UnitedKingdom.Phone:44-207-848-6122;Fax:44-207-848-6123;E-mail:rosalie.ferner@kcl.ac.uk.3D.H.G.wastheleaderofthefollowingworkinggroups:MedicalConsensusGroup,SurgeryConsensusGroup,PathologyConsensusGroup,OncologyConsensusGroup,andMolecularBiologyConsensusGroup.MembersofthegroupsarelistedintheAppendix.4Theabbreviationsusedare:NF1,neurofibromatosis1;MPNST,malignantperipheralnervesheathtumor;MRI,magneticresonanceimaging;18FDG,18F-fluorodeoxyglucose;PET,positronemissiontomography.1573forMPNST,andthelifetimeriskforMPNSTcouldbeashighas10%(14).Themajorityofpatientspresentinthesecondandthirddecadesoflife,andtendtobeyoungerthantheircounterpartswithMPNSTsinthegeneralpopulation(13).WehavealsoidentifiedMPNSTsinNF1patientsasyoungas7yearsandasoldas63yearsofage.CliniciansshouldbealertedtothepossiblediagnosisofMPNSTwhenapatientwithNF1developsunremittingpainnototherwiseexplained,rapidincreaseinsizeofaplexiformneurofibroma,changeinconsis-tencyfromsofttohard,oraneurologicaldeficit.MostNF1-associatedMPNSTsappeartoarisewithinpreexistingplexiformneurofibromas.ThisobservationsuggeststhatindividualswithNF1andplexiformneurofibromaswarrantincreasedsurveillancefordevelopmentofMPNST,andthosewithmanyorveryextensiveplexiformneurofibromasmayhavethehighestrisk.However,thenaturalhistoryofplexiformneurofibromashasnotbeenclearlyde-fined,andthesetumorsmayundergoperiodsofrapidgrowthfollowedbyperiodsofrelativequiescence.Assuch,rapidgrowthisnotalwaysapreludetomalignancy.ThisissueiscurrentlybeingaddressedbyaninternationalstudyusingclinicalassessmentandvolumetricMRI(ClinicalCoordinator,BruceKorf,Boston,MA).Thereisnoevidencethatdermalneurofibromasorflatsuperficialplexiformneurofibromasundergomalignanttransformation,andtheydonotrequireclosemonitoring.Nodularplexiformtumorsassociatedwithlargeperipheralnervesheathsandextensivetumorsinvolvingthebrachial,lumbar,orsacralplexusmaygiverisetoMPNSTsand,therefore,meritheightenedawareness.Plexiformneurofibromas,whicharemorecentrallylocatedandaremoreextensive,appeartohaveahigherlikelihoodofundergoingmalignantchange.Individualswitha“neurofibromatous”neuropathymightalsohaveanincreasedriskofdevelopingMPNST,becausetheydevelopdermalneurofibro-masinearlychildhoodandhavediffuseplexiforminvolvementofthespinalnerverootsandperipheralnerves(15).PatientsinwhomamicrodeletionoftheNF1locusisdetectedtendtohavehighernumbersofdiscretedermalneurofibromasatearlieragesandmighthaveahigherincidenceofMPNSTthantheoverallNF1population(16).TheincreasedriskofMPNSTinthisgroupcouldbereadilytestedbycomparingthefrequencyofNF1microde-letionsdetectedbyfluorescenceinsituhybridizationofperipheralbloodlymphocytesinNF1patientswithandwithoutMPNST.MPNSTsareoftendifficulttodetect,becausetheclinicalindicatorsofmalignancymayalsobefeaturesofactive,benignplexiformneurofibromas.AMRIshouldbeperformedtolocatethesite,extent,andchangeinsizeoftheplexiformneurofibroma,butitdoesnotreliablydeterminemalignanttransformation.Thediffusenatureoftheplexiformneurofibromamayprecludetotalremovalbecauseofim-pingementonsurroundingstructuresandneurologicaldeficit.PETwiththeglucoseanalogue18FDGisadynamicimagingtechnique,whichpermitsthevisualizationandquantificationofglu-cosemetabolismincellsandreflectstheincreaseinmetabolisminmalignanttumors(17,18).Aretrospectivestudyof18NF1patientsdemonstratedthat18FDGPETisapotentiallyuseful,noninvasivemethodfordetectingmalignantchangeinplexiformneurofibromas(19).However,thedistinctionbetweenlow-gradeMPNSTsandbe-nignplexiformneurofibromaswasnotclearinallofthecases.Itisrecommendedthataprospectivestudywithclinical,radiological,andpathologicalcorrelationbeundertakentoevaluatethevalueof18FDGPETinthedetectionofmalignantchangeinNF1.Thenewtracer18F-thymidine,whichdetectsDNAturnover,mightbehelpfulindistinguishinglow-gradeMPNSTsfromactive,benignplexiformneurofibromasinfuturePET-basedstudies.ScrupulousdocumentationofinformationonNF1patientswithMPNSTwillplayavitalpartinoptimizingthemanagementofthiscondition.Datashouldberecordedinastandardizeddatabase,whichshouldbecirculatedtosarcomaunitsandtospecialistsinneurology,genetics,surgery,andoncology,whoarelikelytoencounterthesepatients.Demographicdetails,confirmationofthediagnosisofNF1,historyofcancerintheindividualandfamily,clinicalandradiologicalfeaturesoftheMPNST,andpathologicaldescriptionofthetumorneedtobeincluded.Documentationoftreatmentmodalitiesandoutcomeisessential.ItisanticipatedthatmolecularanalysisofconstitutionalDNAandtumormaterialmayplayapivotalroleindeterminingtherapeuticprotocols.PathologyConsensusGroup.Theoptionsfordiagnosisincludefineneedleaspiration,Tru-Cutneedlebiopsy,openincisionalbiopsy,andexcisionalbiopsy.Fineneedleaspirationisinadequatefortheassessmentoftumortypeandgrade,becausedissociatedtumorcellsareobtainedandarchitecturalrelationshipslost.Tru-Cutneedlebi-opsyisthemethodofchoicewhenundertakeninamultidisciplinaryteamsettingusingexpertradiological,surgical,andpathologicaladvice.Ifsufficienttissuecoresaretakenandthespecimenissentfresh,techniquescanbeusedsuchasimprintcytologytoensurethattumortissueispresent.Representativefreshtissuecorescanbesnapfrozeninliquidnitrogenformolecularbiologicalstudiesandresearch.Anopenincisionalbiopsyprovidesmoretissuefordiagnosisandancillarystudies,butthesampleislimitedtoonesite.Forthisreason,itisnecessarytoensurethatthesampleisrepresentativeandincludestheareassuspectedofmalignancy.Thecombinationofopeninci-sionalbiopsywithmultipleTru-Cutneedlebiopsiesfromdifferentareasmayovercomethisdifficulty.Thistechniqueshouldbecarefullyplannedsothatfuturesurgicalresectionmarginsarenotcompro-mised.Anexcisionalbiopsyshouldbereservedforsmall,superfi-ciallylocatedtumors,whichcanberesectedwithaclearmargin.Thisprovidesthemostmaterialfordiagnosisandresearch.Thetechniqueoftargetedbiopsyusing18FDGPETandmagneticresonanceregis-trationisbeingdevelopedinspecialistcentersandmaybeofpotentialbenefitinthemanagementofthisgroupofheterogeneoustumors.TheminimumhistologicalexaminationshouldcomprisesectionsstainedwithconventionaltinctorialstainsincludingH&Eandretic-ulin.Inaddition,immunohistochemicalstainsforS100protein,theskeletalmusclemarkersdesminandmyogenin,andaproliferationmarker(MIB1)arerequired.Otherspindlecelltumorsmaybeex-cludedwithappropriateimmunohistochemicalmarkers.Inthefuture,theremightbeaplacefortheroutineapplicationofstainsforknowntumorsuppressorgenesoroncogenes(p53,erbB2,p16,andp27),formolecularanalysisofNF1andNF2expression,andfordeterminationofRASactivity(see“MolecularBiologyConsensusGroup”).ThepathologicalfeaturesofMPNSTrevealafusiformorgloboidmassassociatedwithanerve.Necrosis,pseudocysticchange,orhemorrhagemaybefound.Histologically,thetumoriscomposedofspindlecellsarrangedincellularfascicles(20).Divergentdifferenti-ationmayoccur,includingrhabdomyoblasticchangeencounteredinthemalignanttritontumorvariant(20,21).Thepathologicalcriteriaformalignancyincludeinvasionofsur-roundingtissuesbytumorcells,vascularinvasion,markednuclearpleiomorphism,necrosis,andthepresenceofmitoses(20).Evenasinglemitoticfiguremaybesignificant,particularlyinatumorwithhypercellularityandnuclearatypia.Thesignificanceofthemitosesdependsontheprognosticvalueofincreasedcellproliferation.There-fore,themostclinicallyrelevantquestionishowbesttodeterminemalignanttransformationinthesetumors.Themethodsavailableforassessinggrowthrateincludedirectcountingofobservedmitoticfigures,theestimationofproliferationindexusingimmunostains,flowcytometry,othermoleculartechniques,orthedetectionofanimbalancebetweenapoptosisandproliferation.Theaccuratepredic-tionofbiologicalbehaviormaydependontheinterpretationofacombinationofhistologicalandimmunohistochemicalfeatures.1574THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUPThereisahistologicalspectrumofperipheralnervesheathtumorsrangingfromtheclearlybenigntotheclearlymalignant,anditisoftenpossibletodistinguishbetweenhigh-gradeandlow-gradetumors.However,asignificantnumberoftumors,theso-called“atypicalneurofibromas”donotfitintoanydefinedgradingsystem(20,22,23).Thesemaybelocallyaggressivebutarelesslikelytometastasize.Inaddition,thereareafewhistologicallylow-gradetumorsthatbehaveaggressively.Theapplicationofmoleculartechniquestode-terminethegeneexpressionprofilesofgeneexpressioninthesetumorsmayhelppathologiststopredictbiologicalbehaviorandoutcomemoreaccurately.Thecorrelationwithnewimagingtech-niquesmayalsohelptoresolvethisissue.SurgeryConsensusGroup.Theaimofsurgeryiscompletere-movalofthelesionwithtumor-freemargins(13).Biopsyofthelesionisessentialbeforesurgeryisundertaken(see“PathologyGroup”statement).Smalllesionsshouldbewidelyresected,andlargertumorsshouldbeaswidelyexcisedaspossible(ⱖ10cm)toavoidcentripetalspread.Reconstructionofthenerveaftersurgeryforbrachialandlumboscaralplexuslesionsisnotadvocated,becauseitdoesnotrestoreusefulfunctionandmaycompromisetheadequacyofthesurgicalexcision.AmputationmaybeindicatedforextensivetumorsandforMPNST,whichrecurafterapparentlyadequateexcision.PatientsshouldhavebaselineMRI2–3monthsaftersurgery.Ad-ditionalimagingstudiesandtheirtimingwilldependonthepatientsymptomsandthenatureoftheprimarytumor.18FDGPETmightbeausefulscreeninginvestigationinthefuture,becauseitprovidesbothalocalandabody-widescanwithinasingleinvestigationforthisgroupof“at-risk”patients.OncologyConsensusGroup.ItisnotclearwhetherpatientswithNF1andMPNSThaveadifferentclinicalcourseorresponsetotreatmentcomparedwiththeircounterpartsinthegeneralpopulation.ThecurrentmanagementofMPNSTshouldbeidenticaltothatofanyothersofttissuetumorinthatsuccessfultreatmentdependsoncom-pletesurgicalexcision.Radiotherapyprovideslocalcontrolandmaydelaytheonsetofrecurrencebuthaslittleeffectonlong-termsur-vival.Adjuvantradiotherapyshouldbegivenwhereverpossibleforintermediate-tohigh-gradelesionsandforlow-gradetumorsafteramarginalexcision.Chemotherapyforadultsofttissuesarcomasisusuallyconfinedtothetreatmentofmetastaticdisease.Fewdrugshavebeenshowntobeeffective,andtreatmentcomprisessingleagentdoxorubicinoracombinationofdoxorubicinandifosfamide(24).Althoughsuchtreat-mentisnotcurative,itmayachieveusefulpalliationformanypatients,andcomplete,long-lastingremissionsareobservedinrareinstances.Moreover,itmaybeusefulinthepreoperativesettingtodownstagepatientswithunresectableprimaries.MPNSTappearstobeofintermediatechemosensitivity,lessre-sponsivethansynovialsarcoma,butmorechemosensitivethanrefrac-torydiseasessuchasalveolarsoftpartsarcoma.Thepartialresponseratewiththebestavailablechemotherapyislikelytobeintherangeof25–30%(24).Controversysurroundstheuseofadjuvantchemo-therapy.Ameta-analysishasshownasignificantbenefitat10yearsintermsofprogression-freesurvivalforbothlocalanddistantrelapse(25).However,themagnitudeofanyoverallsurvivalbenefitissmall(⬃4%andnotstatisticallysignificant).Chemotherapymightbeusedtoimprovelocaldiseasecontrolformarginallyresectedlesionsatsiteswhereanadequatedoseofradiotherapyisdifficulttodeliver.Recentadvancesinsarcomatherapyhaveresultedfromanim-provedunderstandingofthemolecularbiologyofindividualdiseases.Thediscoveryofmutationsinthec-kitgene,resultinginoverexpres-sionofaconstitutivelyactivatedc-kitmoleculeingastrointestinalstromaltumors,hasbeenofparamounttherapeuticimportance.ThishasnotonlyresultedinCD117overexpressionbecomingthehallmarkdiagnostictestforthisdiseasebuthasleadtoanewformoftreatmentforadiseasethatwashithertountreatable.ThereceptortyrosinekinaseinhibitorSTI571(Glivec)isapotentinhibitorofKITandhasbeenreportedtoresultindramatictumorregressionsinthesepatients,whichthusfarappeartobedurable(26).Similarly,itisthehopethatnewagents,whichtargettheRAS-RAF-mitogen-activatedprotein/ERKkinase-extracellularsignal-regulatedkinasepathway,mayproveeffectiveagainstMPNSTinNF1.Inthesetumors,lossoftheinhibitingfunctionofneurofibrominresultsinincreasedp21-rassignaling.Anti-RASpathwaydrugsin-cludefarnesyltransferaseinhibitors,whichblocktheabilityofRAStoreachthemembranewhereitisactivated(27).However,therearenowspecificinhibitorsoftargetsdownstreamofRAS,suchasmitogen-activatedprotein/ERKkinase,thatarealsobeingdevelopedforclinicalstudy.GiventhesuccessofGlivec,itisclearthattyrosinekinaseinhibitorscanbedevelopedthatarebothselectiveandeffec-tive,andhopefullyoneoftheseagentswillproveeffectiveagainstMPNSTs.MolecularBiologyConsensusGroup.SignificantprogresshasbeenmadeinrecentyearsinelucidatingthemoleculargeneticsandbiologyofMPNSTinNF1.SurgicalspecimensandcelllinesfrompatientswithMPNSTandNF1exhibitlossofNF1gene(neurofibro-min)expressionandhighlevelsofRASactivity(28–30).StudiesofbenignneurofibromasfromNF1patientshavedemonstratedthatlossofNF1geneexpressionandincreasedRASactivationaloneisnotsufficientforMPNSTformation,andthatadditionalgeneticalter-ations(p27-Kip1,p53,andp16)arerequiredformalignanttransfor-mation(31–35).ThegenerationofmicewithtargetedmutationsintheNF1genehasconfirmedthisnotioninthatlossofNF1expressionappearstobesufficientfortheformationoftumorswithpathologicalfeaturesofplexiformneurofibromas,whereasMPNSTdevelopmentisdependentonfunctionalinactivationofp53(36,37).Ourabilitytomoreaccuratelypredicttumorbehaviorandresponsetotherapyislikelytoderivefromstudiesaimedatdefiningthemolecularchangesseeninthesetumors.AvarietyofdifferentgeneticalterationshavebeenreportedinMPNSTs,butitisnotclearthatanyofthesearecausallyrelatedtotumorigenesisormalignantprogres-sion.Moreover,itisnotknownwhetherasubsetofthesechangeswillpredicttheclinicalcourseordefinewhetheraspecificformoftherapyislikelytobemoreefficacious.AdditionalresearchisrequiredtodefinetheintracellularsignalingpathwayabnormalitiesprimarilyresponsibleforplexiformneurofibromaorMPNSTgrowth,andtodelineatewhichspecificdownstreameffectorsofRASmediateRASmitogenicsignaling.Similarly,researcheffortstodefinethegeneticchangesinadditiontoNF1lossthatarerequiredforplexiformneurofibromamalignanttransformationalsomayidentifyadditionaltherapeutictargetsforMPNSTdrugdesign.ThesestudieshavethepotentialtoidentifygeneexpressionprofilesthatarespecificallyassociatedwithparticularMPNSTsubtypesorplexiformneurofibro-masmostlikelytoundergomalignantchange(“molecularfinger-print”).TheimportanceofaninternationaltissuebankforMPNSTstofacilitatebasicscienceandtranslationalresearchcannotbeoverstated.Thiswouldinvolvestoringfresh-frozenspecimens,correspondingnormalnervespecimenswhenavailable,andnormaltissueorblood,aswellasparaffinsections.Thesespecimensneedtobewellchar-acterizedpathologicallyandtobelinkedtomolecular,pathological,andclinical-epidemiologicalpatientdata.BothNF1-associatedandsporadicMPNSTsshouldbestoredinthistumorbanktodeterminewhetherthenotedmolecularandclinical-epidemiologicalcharacter-isticsaresimilarinthesetwogroups.Conclusions.MPNSTisadevastatingcomplicationofNF1,whichshouldbemanagedbymultidisciplinaryteamsofcliniciansand1575THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUPscientistswithexpertiseinthediagnosisandtreatmentofthisdisease.ClinicalandmoleculargeneticstudiesshouldidentifyNF1patientswhoareathighriskofdevelopingMPNST.Theestablishmentofaninternationaldatabasewillpermitthestandardizedrecordingofclin-ical,pathological,andtreatmentdata,andoutcomemeasures.ThedevelopmentofimagingmethodssuchasPETscanningwillaidindistinguishingMPNSTfrombenignplexiformneurofibromas.Recentadvancesinmoleculargeneticshaveprovidedexcitingopportunitiestodeveloptargetedtherapiesforthesetumors,whichwillbehelpedbytheestablishmentofaninternationaltissuebank.Ourabilitytotranslatetheseadvancesintorationalclinicaltrialsrepresentsthechallengefortheimmediatefuture.AcknowledgmentsWethankBruceKorfforcriticalinsightsduringthepreparationofthisdocumentandJ.M.Friedmanforeditorialcomments.SusanHusonproposedthetopicforthisconsensusmeeting.RosalieE.FernerandDavidH.GutmannorganizedtheMPNSTConsensusGroupwithassistancefromMeenaUpadhyaya,DavidViskochil,andRobertaTweedy(BritishNeurofibromatosisAssociation).APPENDIXMedicalConsensusGroup.GarethEvans,DepartmentofMedicalGenetics,St.Mary’sHospital,Manchester,UnitedKingdom;RosalieFerner,DepartmentofClinicalNeurosciences,GKTSchoolofMedicine,Guy’sHospital,London,UnitedKingdom;JanM.Friedman,DivisionofMedicalGenetics,UniversityofBritishColumbia,Vancouver,Canada;SusanHuson,DepartmentofMedicalGenetics,ChurchillHospital,Oxford,UnitedKingdom;ViktorMautner,DepartmentofNeurology,KlinikumNord,Ochsenzoll,Hamburg,Germany;MichaelO’Doherty,ClinicalPETCenter,GKTSchoolofMedicine,St.Thomas’Hospital,London,UnitedKingdom;DavidViskochil,DivisionofMedicalGenetics,UniversityofUtah,SaltLakeCity,UT.SurgeryConsensusGroup.RolfeBirch,PeripheralNerveInjuryUnit,RoyalNationalOrthopaedicHospital,London,UnitedKingdom;IvoDeWever,DepartmentofSurgicalOncology,UniversityHospital,Leuven,Belgium;RheinhardFriedrich,Depart-mentofSurgery,UniversityHospital,Hamburg-Eppendorf,Germany;HenkGiele,De-partmentofPlasticSurgery,RadcliffeInfirmary,Oxford,UnitedKingdom;RobertGrimer,DepartmentOfOrthopaedics,RoyalOrthopaedicHospital,Birmingham,UnitedKingdom;JonathanLucas,SoftTissueTumorUnit,DepartmentofOrthopaedics,Guy’sandSt.Thomas’Hospitals,London,UnitedKingdom;MichaelSmith,SoftTissueTumorUnit,DepartmentofOrthopaedics,Guy’sandSt.Thomas’Hospitals,London,UnitedKingdom;MeirionThomas,SarcomaandMelanomaUnit,RoyalMarsdenHospital,London,UnitedKingdom.PathologyConsensusGroup.CherylCoffin,DivisionofPediatricPathology,Uni-versityofUtahSchoolofMedicine,SaltLakeCity,UT;SusanRobinson,DepartmentofNeuropathology,King’sCollegeHospital,London,UnitedKingdom;AnnSandison,DepartmentofPathology,CharingCrossHospital,London,UnitedKingdom;SusanStandring,DivisionofNeuroscience,Guy’sKing’sandSt.Thomas’SchoolofMedicine,London,UnitedKingdom;AndreasvonDeimling,DepartmentofNeuropathologyCharite´,HumboldtUniversity,Berlin,Germany.OncologyConsensusGroup.AdrianJones,DepartmentofRadiotherapy,ChurchillHospital,Oxford,UnitedKingdom;IanJudson,CRCCenterforCancerTherapeutics,InstituteofCancerResearch,Sutton,UnitedKingdom;ChrisMitchell,DepartmentofPediatricOncology,JohnRadcliffeHospital,Oxford,UnitedKingdom;RifPamukcu,CellPathways,Inc.,Horsham,PA;MikeStevens,DepartmentofPediatricOncology,BirminghamChildren’sHospital,Birmingham,UnitedKingdom;JeremyWhelan,TheMeyersteinInstituteofOncology,TheMiddlesexHospital,London,UnitedKingdom.MolecularBiologyConsensusGroup.AbhijitGuha,LabattsBrainTumorCenter,TheHospitalforSickChildren,Toronto,Ontario,Canada;DavidGutmann,DepartmentofNeurology,WashingtonUniversitySchoolofMedicine,St.Louis,MO;ChrisJones,DepartmentofPathology,UniversityofWalesCollegeofMedicine,Cardiff,UnitedKingdom;EricLegius,CenterforHumanGenetics,UniversityHospital,Leuven,Belgium;AnneMudge,MRCLaboratoryforMolecularBiology,UniversityCollege,London,UnitedKingdom;ThorstenRosenbaum,Children’sHospital,Heinrich-HeineUniversity,Dussledorf,Germany;MeenaUpadhyaya,InstituteofMedicalGenetics,UniversityofWalesCollegeofMedicine,Cardiff,UnitedKingdom.REFERENCES1.Huson,S.M.,Clark,P.,Compston,D.A.S.,andHarper,P.S.AgeneticstudyofvonRecklinghausenneurofibromatosisinSouthEastWales.1:prevalence,fitness,mu-tationrate,andeffectofparentaltransmissiononseverity.J.Med.Genet.,26:704–711,1991.2.Viskochil,D.,Buchberg,A.M.,Xu,G.,Cawthon,R.M.,Stevens,J.,Wolff,R.K.,Culver,M.,Carey,J.C.,Copeland,N.G.,Jenkins,N.A.,White,R.,andO’Connell,P.Deletionsandatranslocationinterruptaclonedgeneattheneurofibromatosistype1locus.Cell,62:187–192,1990.3.Wallace,M.R.,Marchuk,D.A.,Anderson,L.B.,Letcher,R.,Odeh,H.M.,Saulino,A.M.,Fountain,J.W.,Brereton,A.,Nicholson,J.,Mitchell,A.L.,Brownstein,B.H.,andCollins,F.S.Type1neurofibromatosisgene:identificationofalargertranscriptdisruptedinthreeNF1patients.Science(Wash.DC),249:181–186,1990.4.Xu,G.F.,O’Connell,P.,Viskochil,D.,Cawthon,R.,Robertson,M.,Culver,M.,Dunn,D.,Stevens,J.,Gesteland,R.,White,R.,andWeiss,R.Theneurofibromatosistype1geneencodesaproteinrelatedtoGAP.Cell,62:599–608,1990.5.NationalInstitutesofHealthConsensusDevelopmentConferenceStatementNeuro-fibromatosis.Arch.Neurol.,45:575–578,1988.6.Ferner,R.E.Clinicalaspectsofneurofibromatosis1.In:M.UpadhyayaandD.N.Cooper(eds.),Neurofibromatosis1fromGenotypetoPhenotype,pp.21–38.Oxford:BiosScientificPublishersLtd.,1998.7.vonRecklinghausen,F.D.U¨berdieMultiplenFibromederHautundIhreBeziehungzudenMultiplenNeuromen.Berlin:AHirschwald,1882.8.Harkin,J.C.Pathologyofnervesheathtumors.Ann.NYAcad.Sci.,486:147–154,1986.9.Korf,B.R.,Huson,S.M.,Needle,M.,Ratner,N.,Rutkowski,L.,Short,P.,Tonsgard,J.,andViskochil,D.Reportoftheworkinggrouponneurofibroma,pp.4–27.TheNationalNeurofibromatosisFoundation,Inc.,1997.10.Huson,S.M.,Harper,P.S.,andCompston,D.A.S.VonRecklinghausenNeurofi-bromatosis.AclinicalandpopulationstudyinSouthEastWales.Brain,111:1355–1381,1988.11.Waggoner,D.J.,Towbin,J.,Gottesman,G.,andGutmann,D.H.Aclinic-basedstudyofplexiformneurofibromasinneurofibromatosis1.Am.J.Med.Genet.,92:132–135,2000.12.Friedman,J.M.,andBirch,P.H.Type1neurofibromatosis.Adescriptiveanalysisofthedisorderin1,728patients.Am.J.Med.Genet.,70:138–143,1997.13.Ducatman,B.,Scheithauer,B.,Piepgras,D.,Reiman,H.M.,andIlstrup,D.M.Malignantperipheralnervesheathtumors:aclinicopathologicstudyof120cases.Cancer(Phila.),57:2006–2021,1986.14.McGaughran,J.,Harris,D.I.,Donnai,D.,Teare,D.,McLeod,R.,Kingston,H.,Super,M.,Harris,R.,andEvans,D.G.R.Aclinicalstudyoftype1neurofibroma-tosisinNorthWestEngland.J.Med.Genet.,36:197–203,1999.15.Ferner,R.E.,Upadhyaya,M.,Osborn,M.,andHughes,R.A.C.Neurofibromatousneuropathy.J.Neurol.,243:S20,1996.16.Leppig,K.A.,Kaplan,P.,Viskochil,D.,Weaver,M.,Ortenberg,J.,andStephens,K.Familialneurofibromatosis1microdeletions:cosegregationwithdistinctfacialphe-notypeandearlyonsetofcutaneousneurofibromata.Am.J.Med.Genet.,73:197–204,1997.17.Strauss,L.G.,andConti,P.S.TheapplicationsofPETinclinicaloncology.J.Nucl.Med.32:623–648,1991.18.Lucas,J.D.,O’Doherty,M.J.,Wong,J.C.H.,Bingham,J.B.,McKee,P.H.,Fletcher,C.D.M.,andSmith,M.A.Evaluationoffluorodeoxyglucosepositronemissiontomographyinthemanagementofsofttissuesarcomas.J.BoneJointSurg.Br.Vol.,80:441–447,1998.19.Ferner,R.E.,Lucas,J.D.,O’Doherty,M.J.,Hughes,R.A.C.,Smith,M.A.,Cronin,B.F.,andBingham,J.B.Evaluationof18fluorodeoxyglucosepositronemissiontomographyinthedetectionofmalignantperipheralnervesheathtumorsinneuro-fibromatosis1.J.Neurol.Neurosurg.Psychiatry,68:353–357,2000.20.Enziger,F.M.,andWeiss,S.W.Benigntumorsofperipheralnerves:malignanttumorsoftheperipheralnerves.In:W.Sharon,WeissandJ.R.,Goldblum(eds.),SoftTissueTumors,Ed.4,pp.1111–1263.St.Louis,MO:Mosby,2001.21.Masson,P.Recklinghausen’sNeurofibromatosis.SensoryNeuromasandMotorNeuromas.LibmanAnniversaryVolumes2,pp.793–802.NewYork:NewYorkInternationalPress,1932.22.Lin,B.T-Y.,Weiss,L.M.,andMedeiros,L.J.Neurofibromaandcellularneurofi-bromawithatypia.Areportof14tumors.Am.J.Surg.Pathol.,21:1443–1449,1997.23.Coffin,C.M.,andDehner,L.P.Cellularperipheralneuraltumors(neurofibromas)inchildrenandadolescents:aclinicopathologicalandimmunohistochemicalstudy.Pediatr.Pathol.,10:351–361,1990.24.Santoro,A.,Tursz,T.,Mouridsen,H.,Verveij,J.,Steward,W.,Somers,R.,Buesa,J.,Casali,P.,Spooner,D.,andRankin,E.DoxorubicinversusCYVADICversesdoxorubicinplusifosfamideinfirst-linetreatmentofadvancedsofttissuesarcomas:arandomizedstudyoftheEORTCSoftTissueandBoneSarcomaGroup.J.Clin.Oncol.,13:1537–1545,1995.25.SarcomaMeta-analysisCollaboration.Adjuvantchemotherapyforlocalisedresecta-blesoft-tissuesarcomainadults:meta-analysisofindividualdata.Lancet,350:1647–1654,1997.26.VanOosterom,A.T.,Judson,I.,Verweij,J.,DiPaola,E.,VanGlabbeke,M.,Dimitrijevic,S.,andNielsen,O.STI571,anactivedruginmetastaticgastro-intestinalstromaltumors(GIST)anEORTCPhaseIstudy.Proc.Am.Soc.Clin.Oncol.,20:,2001.27.Cox,A.D.Farnesyltransferaseinhibitors:potentialroleinthetreatmentofcancer.Drugs,61:723–732,2001.28.Guha,A.,Lau,N.,Huvar,I.,Gutmann,D.,Provias,J.,Pawson,T.,andBoss,G.Ras-GTPlevelsareelevatedinhumanperipheralnervetumors.Oncogene,12:507–513,1996.29.Basu,T.N.,Gutmann,D.H.,Fletcher,J.A.,Glover,T.W.,Collins,F.S.,andDownward,J.Aberrantregulationofrasproteinsinmalignanttumorcellsfromtype1neurofibromatosispatients.Nature(Lond.),356:663–664,1992.30.DeClue,J.E.,Papageorge,A.G.,Fletcher,J.A.,Diehl,S.R.,Ratner,N.,Vass,W.C.,andLowy,D.R.Abnormalregulationofmammalianp21rascontributestomalignanttumorgrowthinvonRecklinghausen’s(type1)neurofibromatosis.Cell,69:265–273,1992.1576THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUP31.Kluwe,L.,Friedrich,R.E.,andMautner,V.F.AlleliclossoftheNF1geneinNF1-associatedplexiformneurofibromas.CancerGenet.Cytogenet.,113:65–69,1999.32.Rutkowski,J.L.,Wu,K.,Gutmann,D.H.,Boyer,P.J.,andLegius,E.Geneticandcellulardefectscontributingtobenigntumorformationinneurofibromatosistype1.Hum.Mol.Genet.,9:1059–1066,2000.33.Sherman,L.S.,Atit,R.,Rosenbaum,T.,Cox,A.D.,andRatner,N.SinglecellRas-GTPanalysisrevealsalteredRasactivityinasubpopulationofneurofibromaSchwanncellsbutnotfibroblasts.J.Biol.Chem.,275:30740–30745,2000.34.Nielsen,G.P.,Stemmer-Rachamimov,A.O.,Ino,Y.,Moller,M.B.,Rosenberg,A.E.,andLouis,D.N.Malignanttransformationofneurofibromasinneurofibro-matosis1isassociatedwithCDKN2A/p16inactivation.Am.J.Pathol.,155:1879–1884,1999.35.Kourea,H.P.,Cordon-Cardo,C.,Dudas,M.,Leung,D.,andWoodruff,J.M.Theemergingroleofp27kipinmalignanttransformationofneurofibromas.Am.J.Pathol.,155:1885–1891,1999.36.Cichowski,K.,Shih,T.S.,Schmitt,E.,Santiago,S.,Reilly,K.,McLaughlin,M.E.,Bronson,R.T.,andJacks,T.Mousemodelsoftumordevelopmentinneurofibro-matosistype1.Science(Wash.DC),286:2172–2176,1999.37.Vogel,K.S.,Klesse,L.J.,Velasco-Miguel,S.,Meyers,K.,Rushing,E.J.,andParada,L.F.Mousetumormodelforneurofibromatosis1.Science(Wash.DC),286:2176–2179,1999.1577THEMALIGNANTPERIPHERALNERVESHEATHTUMORGROUP